

CORRIGENDUM

Trends in use of psychotropic medications among patients treated with cholinesterase inhibitors in Japan from 2002 to 2010 — Corrigendum

Yasuyuki Okumura, Takashi Togo and Junichi Fujita

doi: 10.1017/S1041610214001975, Published online by Cambridge University Press, 12 September 2014

In the above published article by Okumura *et al.*, the authors apologize for errors in the 2nd, 3rd and 4th columns of [Table 2](#). The corrected [Table 2](#) is given below.

Table 2 Trends in psychotropic visits by psychotropic classes

PSYCHOTROPICS	PSYCHOTROPIC VISITS, %			ODDS RATIOS FOR TIME TREND (95% CI)		
	2002–2004	2005–2007	2008–2010	2002–2004 VERSUS 2005–2007	2005–2007 VERSUS 2008–2010	2002–2004 VERSUS 2008–2010
Antipsychotics	21.3	22.0	21.3	1.11 (0.99, 1.24)	1.03 (0.94, 1.12)	1.14 (1.02, 1.27)*
SGAs	4.9	8.7	11.2	2.02 (1.66, 2.47)*	1.46 (1.30, 1.65)*	2.95 (2.44, 3.59)*
FGAs	17.4	15.2	12.1	0.88 (0.78, 1.00)	0.80 (0.72, 0.89)*	0.71 (0.62, 0.80)*
Antidepressants	10.4	11.3	11.4	1.21 (1.04, 1.41)*	1.08 (0.96, 1.21)	1.30 (1.12, 1.51)*
NGAs	6.0	7.5	7.1	1.37 (1.13, 1.66)*	1.00 (0.87, 1.14)	1.36 (1.13, 1.65)*
TCAs	1.7	1.7	1.7	1.14 (0.80, 1.64)	1.00 (0.76, 1.32)	1.14 (0.81, 1.63)
Others	3.6	3.0	3.8	0.96 (0.74, 1.25)	1.42 (1.17, 1.74)*	1.37 (1.08, 1.75)*
Mood stabilizers	1.6	1.9	2.8	1.46 (1.02, 2.12)*	1.58 (1.24, 2.01)*	2.30 (1.65, 3.28)*
Sedatives-hypnotics	25.7	27.1	27.3	1.08 (0.97, 1.20)	1.04 (0.96, 1.12)	1.11 (1.01, 1.24)*
Any BZDs	21.7	22.1	21.8	1.02 (0.91, 1.14)	1.00 (0.92, 1.09)	1.02 (0.92, 1.14)
Sedative BZDs	12.1	13.2	11.9	1.11 (0.96, 1.28)	0.90 (0.81, 1.00)*	1.00 (0.87, 1.14)
Hypnotics BZDs	16.7	17.0	17.2	1.02 (0.90, 1.15)	1.04 (0.95, 1.14)	1.06 (0.94, 1.19)
Z-drugs	4.7	6.6	7.4	1.43 (1.17, 1.77)*	1.17 (1.01, 1.34)*	1.67 (1.37, 2.04)*
Others	1.7	1.9	1.3	1.26 (0.89, 1.82)	0.68 (0.52, 0.91)*	0.86 (0.60, 1.25)

Note. BZDs = benzodiazepines; CI = confidence interval; FGAs = first-generation antipsychotics; NGAs = new-generation antidepressants; SGAs = second-generation antipsychotics; TCAs = tricyclic antidepressants.

* $p < .05$

The following corrections related to [Table 2](#) have also been made to the article:

ABSTRACT (Results)

Results: In 2008–2010, the most prevalently prescribed psychotropic medications to patients with dementia were sedatives-hypnotics (27.3%), antipsychotics (21.3%), antidepressants (11.4%), and mood-stabilizers (2.8%). Between 2002–2004 and 2008–2010, use of second-generation antipsychotics increased from 4.9% to 11.2%, while use of first-generation antipsychotics decreased from 17.4% to 12.1%.

Results: (paragraph 4)

In 2008–2010, the most prescribed psychotropic classes were sedatives-hypnotics (27.3%), antipsychotics (21.3%), antidepressants (11.4%), and mood-stabilizers (2.8%).

Results: (paragraph 5)

Figure 1 shows major results of trends in antipsychotics use between 2002 and 2010. Amongst the antipsychotics, prevalent utilization of SGAs markedly increased from 4.9% to 11.2% (OR 2.95, 95% CI 2.44–3.59), while the use of FGAs declined from 17.4% to 12.1% (OR 0.71, 95% CI 0.62–0.80) between 2002–2004 and 2008–2010.

Results: (paragraph 6)

Amongst the antidepressants, prevalent utilization of NGAs slightly increased from 6.0% to 7.1% (OR 1.36, 95% CI 1.13–1.65), and other antidepressants increased from 3.6% to 3.8% (OR 1.37, 95% CI 1.08–1.75) between 2002–2004 and 2008–2010.

Results: (paragraph 8)

Amongst the sedatives-hypnotics, the most prescribed subclasses were hypnotic BZDs (17.2%), Sedative BZDs (11.9%), z-drugs (7.4%), and other sedatives-hypnotics (1.3%) in 2008–2010. Between 2002–2004 and 2008–2010, the prevalent utilization of z-drugs increased from 4.7% to 7.4% (OR 1.67, 95% CI 1.37–2.04) although use of any BZDs, sedative BZDs, hypnotic BZDs, and other sedatives-hypnotics remained stable.

Discussion (paragraph 1)

Our study yielded six major findings using data collected from outpatients with dementia. First, we observed a 1.1-fold increase in the extensive use of antipsychotics (about 21%) over time.

Discussion (paragraph 3)

We observed a stable non-negligible use of sedative BZDs (12%) over time.

The corrections do not alter the conclusions of this article and the authors regret these errors.

Reference

Okumura, Y., Togo, T. and Fujita, J. Trends in use of psychotropic medications among patients treated with cholinesterase inhibitors in Japan from 2002 to 2010. *International Psychogeriatrics*, Published online, 12 September 2014, doi: 10.1017/S1041610214001975.